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Background: Exercise-induced pulmonary arterial hypertension (EIPH) in systemic sclerosis (SSc) has already
been observed but its determinants remain unclear. The aim of this study was to determine the incidence and
the determinants of EIPH in SSc.
Methods and results:We prospectively enrolled 63 patients with SSc (age 54 ± 3 years, 76% female) followed in
CHU Sart-Tilman in Liège. All patients underwent graded semi-supine exercise echocardiography. Systolic pulmo-
nary arterial pressure (sPAP) was derived from the peak velocity of the tricuspid regurgitation jet and adding the
estimation of right atrial pressure, both at rest and during exercise. Resting pulmonary arterial hypertension (PH)
was deﬁned as sPAP N35 mm Hg and EIPH as sPAP N50 mm Hg during exercise. The following formulas were
used: mean PAP (mPAP) = 0.61 × sPAP + 2, left atrial pressure (LAP) = 1.9 + 1.24 × left ventricular (LV) E/e′
and pulmonary vascular resistance (PVR) = (mPAP–LAP) / LV cardiac output (CO) and slope of mPAP–LVCO rela-
tionship=changes inmPAP / changes in LVCO. Resting PHwaspresent in 3 patients (7%) and 21patients developed
EIPH (47%). Patients with EIPH had higher resting LAP (10.3 ± 2.2 versus 8.8 ± 2.3 mm Hg; p = 0.03), resting
PVR (2.6 ± 0.8 vs. 1.4 ± 1.1 Woods units; p = 0.004), exercise LAP (13.3 ± 2.3 vs. 9 ± 1.7 mm Hg; p b 0.0001),
exercise PVR (3.6 ± 0.7 vs. 2.1 ± 0.9 Woods units; p = 0.02) and slope of mPAP–LVCO (5.8 ± 2.4 vs. 2.9 ±
2.1 mm Hg/L/min; p b 0.0001). After adjustment for age and gender, exercise LAP (β= 3.1 ± 0.8; p = 0.001)
and exercise PVR (β= 7.9 ± 1.7; p = 0.0001) were independent determinants of exercise sPAP.
Conclusion: EIPH is frequent in SSc patients and is mainly related to both increased exercise LV ﬁlling pressure and
exercise PVR.© 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Systemic sclerosis (SSc) is a rare and complex disease, characterized
by an extensive vasculopathy associated with auto-antibodies and
ﬁbrosis, with a multifactorial etiology [1]. Pulmonary arterial hyperten-
sion (PH), resulting from a pre-capillarymechanism,may be frequent in
SSc with an approximated incidence of 8% to 13%, leading to an in-
creased morbidity and mortality [2]. Echocardiography is an accurate
non-invasive tool for the daily-life screening of patients at risk of PH
[3]. Exercise echocardiography assessment of the pulmonary circulatoryuced pulmonary arterial hyper-
,mean pulmonary arterial pres-
monary arterial pressure; PVR,
, University Hospital, Université
l.: +32 4366 71 94; fax: +32
, plancellotti@chu.ulg.ac.be
.system has evolved over these last few years [4–6] and exercise-
induced PH (EIPH) has recently been suggested as a potential useful
tool for the early identiﬁcation of patients with SSc at risk of developing
resting PH [7,8]. It seems however, that the incidence of EIPHmay over-
estimate the percentage of onset of resting PH during follow-up [9].
Some recent studies have underlined that the origin of EIPH in SSc
could be secondary, not only to pulmonary vasculopathy, but also to
myocardial [10] and/or pulmonary impairment [11,12]. Therefore, a
post-capillary involvement in EIPH has been hypothesized in the litera-
ture [13,14]. Hitherto, the echocardiographic determinants of EIPH in
SSc remain unclear. The present study sought to evaluate the incidence
of EIPH and its determinants in patients with SSc.
2. Methods
We prospectively studied 68 consecutive patients from January 2008 to November
2012 with a diagnosis of SSc, followed in the rheumatology center of CHU Sart-Tilman
in Liège. Five patients refused the study protocol. Exclusion criteria were: (1) inability to
provide informed consent, (2) previous ischemic heart or valvular heart diseases and
(3) inability to perform an exercise test. Eighteen patients were excluded, 15 due to
Fig. 1. Resting and exercise systolic pulmonary arterial pressure in the whole population.
sPAP indicates systolic pulmonary arterial pressure; EIPH indicates exercise-induced pul-
monary arterial hypertension.
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nary diseases, 1 for moderate mitral regurgitation and 2 for known coronary artery dis-
eases. Informed consent was obtained from each patient. The study protocol conforms
to the ethical guidelines of the 1975Declaration of Helsinki as reﬂected in a priori approval
by the institution's human research committee.
All patients underwent a comprehensive resting echocardiography using convention-
al method with a Vivid 9 ultrasound system (General Electric Healthcare, Little Chalfont,
UK). Ofﬂine analysis was performed retrospectively using a customized software package
(EchoPac). Left ventricular (LV) stroke volume were calculated as the difference between
LV end-diastolic and systolic volumes assessed by the bi-apical Simpson diskmethod and
LV ejection fraction was derived as the ratio stroke volume/LV end-diastolic volume.
Cardiac output (CO) was obtained by multiplying LV SV and heart rate. Left atrial area
was measured in apical 4-chamber view at end-systole by planimetry. Peak E- and peak
A-wave velocities of themitral inﬂowweremeasuredwith pulsed-wave Doppler. Doppler
tissue imaging was applied for measurement of the e′ wave at the lateral mitral annulus
aspect.
The following right ventricular echocardiographic parameters were assessed: right
ventricular end-diastolic and end-systolic areas, right ventricular fractional area change,
tricuspid annular plane systolic excursion from an automated M-mode applied on the
right ventricular apical 4-chamber view andmaximal systolic velocity of the tricuspid an-
nulus derived from Doppler tissue imaging pulsed-wave at the lateral tricuspid annulus.
The systolic pulmonary arterial pressure (sPAP)was derived from themaximal veloc-
ity of tricuspid regurgitant jet according to the simpliﬁed Bernoulli equation and adding
right atrial pressure, estimated from the dimension and collapsibility of the inferior vena
cava, according to the American guidelines [15]. A peak value N35mmHgwas considered
to deﬁne resting PH [16]. At peak exercise, sPAPwas derived from themaximal velocity of
tricuspid regurgitant jet and adding 10 mm Hg for the estimation of the right atrial
pressure, as previously validated [17,18]. EIPH was deﬁned as a sPAP N50 mm Hg [19].
ThemPAPwas estimated by the Chemla formula:mPAP= 0.61 × sPAP+ 2. As previously
described [20,21], left atrial pressure (LAP) was assessed by 1.9 + 1.24 LV E/e′ and
pulmonary vascular resistance (PVR) was estimated as the ratio between (mPAP–LAP)
and LVCO, both at rest and at peak exercise. The slope of mPAP/LVCO relationship was es-
timated as the ratio between changes (peak–rest value) in mPAP and changes in LVCO
[19]. All measurements were performed according to the current European Association
of Echocardiography/American Society of echocardiography recommendations [22].
A symptom-limited graded bicycle exercise was performed in a semi-supine
position on a tilted table. After an initial workload of 25 W maintained for 2 min,
the workload was gradually increased by 25 W every 2 min. A 12-lead ECG was mon-
itored continuously, and blood pressure was measured and rest and at each level of
exercise. All patients presented normal tests, deﬁned as the absence of the occurrence of
1) angina, 2)≥2-mmST-segment depression comparedwith baseline level or 3) complex
ventricular arrhythmias.
All patients underwent standard pulmonary function tests with assessment of total
lung capacity, vital capacity, forced vital capacity, forced expiratory volume in 1 s, ratio
of forced expiratory volume in 1 s upon vital capacity and diffusing capacity of the lung
for carbon monoxide.
Continuous variables are expressed as means ± standard deviation; categorical
variables are presented as numbers and percentages. Data comparisons were performed
according to the presence or absence of EIPH using Student unpaired and paired t test,
χ2 test or Fischer exact test as appropriate. The relationships between exercise sPAP and
other continuous variables (i.e., demographic data, resting and exercise echocardiographic
data) were evaluated by simple linear regression. Independent determinant of exercise
sPAP were obtained with the use of multiple linear regression. Values of p b0.05 were
considered statistically signiﬁcant. All statistical analyses were performed with JMP
version 10.0.2.Fig. 2. Comparison of the slope of mean pulmonary arterial pressure and left ventricular
relationships between the two groups. Slope of mPAP–LVCO indicates the ratio between
change inmean pulmonary arterial pressure and change in left ventricular cardiac output;
EIPH indicates exercise-induced pulmonary arterial hypertension.3. Results
3.1. Population characteristics
Fifteen patients were excluded due to unquantiﬁable sPAP, 1 for
moderate mitral regurgitation and 2 for known coronary artery dis-
eases. Among the remaining 45 patients, 47% developed EIPH (n =
21). The sPAP increased signiﬁcantly during exercise (from 25 ± 7 to
46 ± 14 mm Hg; p b 0.0001). Patients with EIPH had higher resting
sPAP (29 ± 6 vs. 21 ± 5 mm Hg; p b 0.001), resting mPAP (20 ± 4 vs.
14 ± 3 mm Hg; p b 0.0001), exercise sPAP (58 ± 9 vs. 36 ±
8 mm Hg; p b 0.0001, Fig. 1), exercise mPAP (37 ± 6 vs. 24 ±
5 mm Hg; p b 0.0001) and slope of mPAP–LVCO relationship (5.8 ±
2.4 vs. 2.9 ± 2.1 mm Hg/L/min; p b 0.0001, Fig. 2). In addition, all pa-
tients with resting PH (n = 3, 7%) developed EIPH. Patients with EIPH
were signiﬁcantly older (62 ± 12 vs. 48 ± 11 years; p = 0.0001),
more frequently female (90% vs. 62%, p= 0.03), had higher resting sys-
tolic blood pressure (139±22vs. 122±18mmHg; p= 0.03) and rest-
ing pulse pressure (62± 16 vs. 50 ± 11mmHg; p= 0.02). There wereno signiﬁcant differences between the 2 groups regarding variables of
lung function tests (Table 1).3.2. Resting and exercise echocardiography
At rest (Table 2), patients of the EIPH group had signiﬁcantly lower
RV end-diastolic area (12.5 ± 3.1 vs. 14.9 ± 4.3 cm2; p = 0.04) higher
resting PVR (2.6± 0.8 vs. 1.4± 1.1 vs.Woods unit; p= 0.0004), higher
LV E/e′ ratio (6.8±1.8 versus 5.5±1.8; p= 0.03), as a result of a lower
e′ (11 ± 3 versus 13 ± 3 cm/s; p = 0.03), and higher LAP (10.3 ± 0.5
vs. 8.8 ± 2.3 mm Hg, p = 0.03), as compared to patients of the
no EIPH group. During exercise, EIPH group exhibited (Table 3) higher
LV E/e′ ratio resulting from lower value of e′ (respectively: 9.2 ± 1.8
vs. 5.7 ± 1.4; p b 0.0001 and 13 ± 1 vs. 17 ± 4 cm/s; p = 0.01),
higher LAP (13.3± 2.3 vs. 9 ± 0.5 mmHg; p b 0.0001). The LVCO sig-
niﬁcantly increased from rest to exercise in all patients (3.7 ± 0.9 vs.
7.2 ± 2.0 L/min; p b 0.001, Fig. 3), but in a lower extent in the EIPH
group (4.2 ± 1.9 vs. 3.0 ± 1.3 L/min; p = 0.04) and patients of this
group had a signiﬁcantly lower resting LV end-systolic volume (25 ±
6 vs. 31 ± 11 mL; p = 0.04) and exercise-induced changes in LV end-
diastolic diameter in the EIPH group (−8 ± 25 vs. 24 ± 46 mm; p =
0.002). Exercise PVR was signiﬁcantly higher in patients with EIPH
(3.6 ± 0.7 vs. 2.1 ± 0.9 Woods units; p b 0.0001).
Table 1
Demographic, clinical, and exercise data.
Variables Whole cohort (n = 45) No EIPH (n = 24, 53%) EIPH (n = 21, 47%) p
Demographic and clinical data
Age, years 54 ± 13 48 ± 11 62 ± 12 0.0001
Female gender, n (%) 34 (76) 15 (62) 19 (90) 0.03
Body mass index, kg/m2 24 ± 5 24 ± 5 24 ± 5 1
Heart rate, bpm 73 ± 13 75 ± 13 72 ± 13 0.38
Systolic arterial pressure, mm Hg 131 ± 22 122 ± 18 139 ± 22 0.03
Diastolic arterial pressure, mm Hg 74 ± 11 72 ± 11 77 ± 10 0.19
Pulse pressure, mm Hg 56 ± 15 50 ± 11 62 ± 16 0.02
Pulmonary function
Total lung capacity, % predicted 93 ± 21 94 ± 22 92 ± 21 0.75
Vital capacity, % predicted 104 ± 24 110 ± 25 99 ± 23 0.18
Force vital capacity, % predicted 101 ± 21 104 ± 21 99 ± 22 0.42
FEV1, % predicted 95 ± 21 97 ± 21 94 ± 21 0.69
FEV1/vital capacity, % predicted 99 ± 12 98 ± 11 100 ± 18 0.56
DLCO, % predicted 65 ± 14 67 ± 14 63 ± 15 0.45
Risk factors
Systemic hypertension, n (%) 5 (11) 1 (4) 4 (19) 0.12
Hypercholesterolemia, n (%) 9 (20) 2 (9) 7 (33) 0.04
Diabetes mellitus, n (%) 0 0 0 NA
Active smoker, n (%) 9 (20) 8 (35) 1 (5) 0.01
Family history of CV disease, n (%) 0 0 0 NA
Medication
ACE inhibitors, n (%) 4 (10) 1 (45) 3 (15) 0.29
β-Blockers, n (%) 4 (10) 0 (0) 4 (25) NA
Diuretic, n (%) 2 (5) 1 (5) 1 (5) 1
Calcium channel blockers, n (%) 22 (55) 13 (65) 9 (45) 0.20
Corticoids, n (%) 12 (30) 5 (25) 7 (35) 0.49
Immunosuppressors, n (%) 7 (17.5) 4 (20) 3 (15) 0.68
Exercise data
Workload, W 74 ± 31 86 ± 31 65 ± 28 0.052
Duration of exercise, min 4.7 ± 1.3 4.6 ± 1.3 5 ± 1.3 0.30
Heart rate, bpm 118 ± 18 118 ± 17 117 ± 19 0.20
Systolic arterial pressure, mm Hg 169 ± 22 162 ± 24 175 ± 16 0.11
Diastolic arterial pressure, mm Hg 82 ± 11 79 ± 9 85 ± 13 0.19
Pulse pressure, mm Hg 86 ± 15 83 ± 18 90 ± 11 0.17
EIPH indicates exercise-induced pulmonary arterial hypertension; FEV1, forced expiratory volume in 1 s; DLCO, diffusing capacity of the lung for carbon monoxide; ACE, angiotensin
converting enzyme; and CV, cardio-vascular.
375D. Voilliot et al. / International Journal of Cardiology 173 (2014) 373–3793.3. Determinants of exercise sPAP
Asigniﬁcant correlationwas foundbetweenexercise sPAP and exercise
LAP (r2 = 0.61, p b 0.0001, Fig. 3), exercise-induced changes in LV end-
diastolic diameter (r2 = 0.26, p = 0.0013) and age (r2 = 0.20, p =
0.002) (Table 4). Exercise LAP was correlated with exercise LA
area (r2 = 0.32, p = 0.02, Fig. 4). Exercise PVR was signiﬁcantly as-
sociated with exercise sPAP (r2 = 0.57; p = 0.0004, Fig. 5). After ad-
justment for age and gender, resting PVR (β = 6.2 ± 1.5; p =
0.0001), exercise LAP (β = 3.1 ± 0.8; p = 0.001) and exercise
PVR (β= 7.9 ± 1.7; p = 0.0001) remained independently associated
with exercise sPAP. In multiple linear regression (model including age
and gender, exercise LAP and exercise PVR), female gender (β= 6.8 ±
2.8; p = 0.03), exercise LAP (β= 1.9 ± 0.6; p = 0.005) and exercise
PVR (β=6.8±1.4; p b 0.001) remained signiﬁcantly associatedwith ex-
ercise sPAP.
4. Discussion
The present study shows that (1) EIPH is common in patientswith SSc
(47%), (2)mainmechanisms explaining EIPH are increased estimated ex-
ercise LV ﬁlling pressure and increased PVR and (3) taking into account
the main factors generally considered as inﬂuencing sPAP (e.g. age, CO
or pulmonary disease), the relationship between estimated exercise LV
ﬁlling pressure, exercise PVR and exercise sPAP remains signiﬁcant.
4.1. Incidence of EIPH in SSc
EIPH is not rare in SSc, even in young patients. Alkotob et al. [7]
found an incidence of 46%. More recently, Gargani et al. [19] haveshown an incidence of 42% in a population of 164 patients with SSc. Of
note, mean age of the population in these studies was relatively similar.
Even if the criterion used to deﬁne the presence of EIPH (sPAP increase
≥ 20 mm Hg [23], or exercise sPAP N 50 mm Hg [19]), the incidence of
EIPH reported remained almost similar. Our results conﬁrm and extend
these previous studies [7,23,19] showing a rate of 47% of EIPH in a
population with a mean age of 54-year old.4.2. Mechanisms of EIPH in SSc
In our study, mainmechanisms explaining the difference in exercise
sPAP between the 2 groups are 1) higher exercise estimated LV ﬁlling
pressure and 2) higher exercise PVR.
Thus, our results support the presence of a sub-clinical LV diastolic
dysfunction [24]. The presence and prognostic value of sub-clinical dia-
stolic dysfunction has already been demonstrated in various diseases
[25,26]. Studies based on right heart catheterization have also reported
a high rate of exercise diastolic impairment in SSc. However, the mech-
anisms involved in this dysfunction were not clearly identiﬁed [13] and
several mechanisms have been suggested. In SSc, diastolic dysfunction
depends not only on classical risk factors such as age, hypertension or
diabetes but also on other speciﬁc factors such as the chronicity of
disease [27] and micro-vascular impairment [28].
We found a low incidence of diabetes and hypertension. However,
this is not in contradiction with the increase in exercise LV ﬁlling
pressure. Our population was relatively “young” (54 ± 13 years) and
included a high percentage of female gender (76%), partly explaining
this fact. These results are consistent with other studies [14,19] with
relatively similar population (mean age from 54 to 58 years and male
gender from 7 to 9%). The authors also found low incidence of diabetes
Table 2
Resting echocardiographic data.
Variables Whole cohort (n = 45) No EIPH (n = 24, 53%) EIPH (n = 21, 47%) p
Resting LV echocardiographic data
LV end-diastolic volume, mL 79 ± 19 84 ± 24 74 ± 12 0.10
LV end-systolic volume, mL 28 ± 9 31 ± 11 25 ± 6 0.04
LV stroke volume, mL 51 ± 12 53 ± 15 50 ± 9 0.45
LVEF Simpson, % 65 ± 6 63 ± 4 66 ± 7 0.12
CO, L/min 3.7 ± 0.9 3.9 ± 1.1 3.5 ± 0.7 0.19
E, m/s 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.89
E deceleration time, ms 178 ± 37 172 ± 30 187 ± 43 0.15
A′, m/s 0.7 ± 0.2 0.6 ± 0.2 0.7 ± 0.2 0.32
E/A′ ratio 1.1 ± 0.5 1.1 ± 0.4 1.1 ± 0.6 0.82
e′, cm/s 12 ± 3 13 ± 3 11 ± 3 0.03
E/e′ ratio 6.0 ± 1.9 5.5 ± 1.8 6.8 ± 1.8 0.03
LAP, mm Hg 9.4 ± 2.4 8.8 ± 2.3 10.3 ± 2.2 0.03
LV eccentricity index 92 ± 12 90 ± 11 94 ± 13 0.31
Resting RV echocardiographic data
RV/LV ratio 74.4 ± 8.6 74.5 ± 9.3 74.3 ± 8.1 0.94
RV end-diastolic area, cm2 13.7 ± 3.9 14.9 ± 4.3 12.5 ± 3.1 0.04
RV end-systolic area, cm2 7.2 ± 2.5 7.9 ± 2.4 6.5 ± 2.4 0.09
RVFAC, % 47.8 ± 8.8 47.3 ± 7.4 48.2 ± 10.2 0.75
TAPSE, mm 23 ± 5 23 ± 5 23 ± 5 0.72
s′, cm/s 12.2 ± 2.7 12.1 ± 3.1 12.4 ± 2.2 0.68
ICV max, cm/s 11.7 ± 4.0 11.6 ± 4.1 11.9 ± 4.0 0.79
IVRT, ms 46 ± 23 47 ± 5 44 ± 5 0.66
MPI 0.35 ± 0.14 0.34 ± 0.10 0.36 ± 0.17 0.61
Pulmonary acceleration time, ms 138 ± 34 141 ± 35 133 ± 33 0.47
Resting PVR, WU 1.9 ± .12 1.4 ± 1.1 2.6 ± 0.8 0.0004
sPAP, mm Hg 25 ± 7 21 ± 5 29 ± 6 b0.0001
mPAP, mm Hg 17 ± 4 14 ± 3 20 ± 4 b0.0001
Resting atrial area
LA, cm2 14 ± 4 14 ± 3 15 ± 5 0.24
RA, cm2 12 ± 4 12 ± 3 12 ± 5 0.96
EIPH indicates exercised-induced pulmonary hypertension; SV, stroke volume; LVEF, left ventricular ejection fraction; CO, cardiac output; LAP, left atrial pressure; RVFAC, right ventricular
fractional area change; TAPSE, tricuspid annular plane systolic excursion; ICV, isovolumic contraction velocity; IRVT, isovolumic relaxation time;MPI,myocardial performance index; sPAP,
systolic pulmonary arterial pressure; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; WU, Woods unit, RA, right atrial; and LA, left atrial.
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sub-clinical diastolic dysfunction could also be the result of other
mechanisms.
First, microvascular ischemia [29] may increase LV stiffness and re-
duce LV compliance, leading to an increased in estimated LVﬁlling pres-
sure. This phenomenon was previously reported by Bulkley et al. [30]
who highlighted diffuse patchy ﬁbrosis on histological examinations,
with contraction band of necrosis unrelated to epicardial coronary ar-
tery stenosis. In addition, James et al. [31] revealed concentric intimal
hypertrophy associated with ﬁbrinoid necrosis of intramural coronary
arteries. Some authors demonstrated microvascular ischemia by single
photon emission computed tomography study of myocardial perfusion.
Myocardial scintigraphy demonstrated evidence of reversible ischemia
together with irreversible lesions and showed inducible of coronary
vasospasm by cold pressor provocation, suggesting both myocardial is-
chemia and ﬁbrosis [32]. Steen et al. [33] demonstrated that exercise-
induced perfusion defects seen by scintigraphy predict onset of cardiac
diseases and death. Several studies emphasized the key role of micro-
vascular ischemia due to vasospasm and demonstrated the beneﬁcial
effect of vasodilator agents on perfusion abnormalities [34]. Vignaux
et al. [35] demonstrated the link between micro-vascular ischemia
and systolic and/or diastolic function. They showed an increase in
systolic and diastolic function, as assessed with strain rate, after admin-
istration of nifedipine in patients with SSc. At the same time, they
showed an increase in perfusion, as assessed by magnetic resonance
imaging, suggesting that increase in myocardial perfusion was the
main determinant of the increase in systolic and diastolic function in
this population. All these studies highlighted that micro-vascular
function has a key role in the pathophysiology of systolic and diastolic
myocardial dysfunction in SSc.
Of note, the absence of kinetic disorders, chest pain or ECG changes
in our study does not exclude this mechanism. In fact, considering theischemic cascade [36], diastolic dysfunction appears early after perfu-
sion abnormalities and before systolic dysfunction, ECG changes and
chest pain.
The second mechanism could be related to a poor exercise adapta-
tion of the systemic vascular system resulting to an excessive arterial
stiffness. Several studies have highlighted arterial systemic stiffness in
SSc [28–30], with heterogeneous impairment of large-vessels [37].
Cheng et al. have recently conﬁrmed increased stiffness in systemic vas-
cular system of SSc patients with a reduction of elastic properties of ca-
rotid artery [38]. Of note, in our study, despite higher pulse pressure at
rest in the EIPH group, there was no signiﬁcant difference during exer-
cise. Pulse pressure depends on stroke volume and arterial compliance.
We did not ﬁnd signiﬁcant differences between the 2 groups in terms of
stroke volume, suggesting a lower systemic vascular compliance in the
EIPH group. Interestingly, Cheng et al. showed increased stiffness in
elastic arterial (carotid) andnot inmuscular artery (femoral) suggesting
different elastic properties depending on the type of artery. Moreover,
Liu et al. [37] demonstrated preferential macro-vasculopathy on aorta
(elastic artery), possibly explaining why pulse pressure measured at
the upper arm (muscular artery) was not different during exercise in
our population.
We also demonstrated that there might be pulmonary vascular im-
pairment in this population, with higher exercise PVR in the EIPH
group. This phenomenon is well known in SSc patients andmay explain
the onset of resting PH. Pulmonary arterial stiffness is due to pulmonary
vascular remodeling, in situ thrombosis but also inﬁltration of in-
ﬂammatory cells leading to endothelial proliferation. Even in the
subset of patients with no EIPH, we found an abnormal increase of
PVR (N3Wood units) in 21% of them. This result is in linewith previous
study from Gargani et al. [19] demonstrating a change of 3.1 ±
2.7 mm Hg/L/min in the subset of patients with exercise sPAP
b50 mm Hg. The authors also analyzed a sub-group of patients with
Table 3
Exercise echocardiographic data.
Variables Whole cohort (n = 45) No EIPH (n = 24, 53%) EIPH (n = 21, 47%) p
Exercise LV echocardiographic data
LV end-diastolic volume, mL 88 ± 22 93 ± 24 82 ± 16 0.13
LV end-systolic volume, mL 27 ± 9 29 ± 10 25 ± 6 0.18
LV stroke volume, mL 61 ± 16 64 ± 17 57 ± 13 0.14
LVEF Simpson, % 70 ± 6 70 ± 6 70 ± 5 1.00
CO, L/mn 7.2 ± 2.0 7.7 ± 2.4 6.5 ± 1.2 0.08
Delta CO, L/mn 3.5 ± 1.6 4 ± 1.7 3 ± 1.3 0.10
E, m/s 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.2 0.52
E dec time, ms 121 ± 39 120 ± 41 112 ± 37 0.89
A′, m/s 0.9 ± 0.2 0.9 ± 0.1 1.0 ± 0.2 0.12
E/A′ ratio 1.1 ± 0.2 1.1 ± 0.2 1.0 ± 0.1 0.54
e′, cm/s 16 ± 4 17 ± 4 13 ± 1 0.01
E/e′ ratio 6.8 ± 2.2 5.7 ± 1.4 9.2 ± 1.8 b0.0001
LAP, mm Hg 10.3 ± 2.8 9 ± 1.7 13.3 ± 2.3 b0.0001
Changes in LAP, mm Hg 1.4 ± 2.2 0.8 ± 2.2 3.1 ± 1.4 0.03
Exercise RV echocardiographic data
RV end-diastolic area, cm2 12.1 ± 3.0 12.6 ± 3.1 11.6 ± 2.9 0.41
RV end-systolic area, cm2 5.7 ± 1.6 6.1 ± 2.0 5.2 ± 1.0 0.15
RVFAC, % 52.6 ± 10.0 51.4 ± 10.4 53.6 ± 10.1 0.60
LV end-diastolic diameter, mm 39 ± 5 42 ± 5 36 ± 3 0.0005
RV/LV ratio 72 ± 12 67 ± 10 77 ± 13 0.03
TAPSE, mm 27 ± 5 26 ± 3 28 ± 7 0.20
s′, cm/s 16.4 ± 3.7 16.9 ± 4.2 15.8 ± 2.9 0.44
ICV max, cm/s 15.5 ± 4.7 15.3 ± 5.9 15.9 ± 2.7 0.78
IVRT, ms 39 ± 17 37 ± 5 40 ± 5 0.64
sPAP, mm Hg 46 ± 14 36 ± 8 58 ± 9 b0.0001
mPAP, mm Hg 30 ± 8 24 ± 5 37 ± 6 b0.0001
Changes in mPAP, mm Hg 13 ± 6 10 ± 4 17 ± 6 b0.0001
Slope of mPAP–LVCO, mm Hg/L/min 4.2 ± 2.6 2.9 ± 2.1 5.8 ± 2.4 0.002
PVR, WU 2.5 ± 1.1 2.1 ± 0.9 3.6 ± 0.7 0.01
Exercise atrial area
LA area,cm2 14 ± 5 14 ± 4 15 ± 6 0.36
RA area, cm2 13 ± 4 12 ± 3 13 ± 6 0.50
EIPH indicates exercised-induced pulmonary hypertension; SV, stroke volume; LVEF, left ventricular ejection fraction; CO, cardiac output; Delta CO, exercise induced change in cardiac
output; LAP, left atrial pressure; RVFAC, right ventricular fractional area change; TAPSE, tricuspid annular plane systolic excursion; ICV, isovolumic contraction velocity; IRVT, isovolumic
relaxation time; MPI, myocardial performance index; sPAP, systolic pulmonary arterial pressure; mPAP, mean pulmonary arterial pressure; changes in mPAP, exercise induced change in
mPAP; slope of mPAP, ratio between changes in mPAP and changes in LVCO; PVR, pulmonary vascular resistance; RA, right atrial; and LA, left atrial.
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normal increase of PVR at peak exercise was present (approximately
around 25%, from 1.6 at rest to 2.0 Wood units at peak exercise),
as compared to controls. These results may suggest that even in sub-
group of patients with low risk factors of PH, pulmonary micro-
vascular impairment may be present.
Finally, abnormal increase in sPAP in SSc may result from both pre-
and post-capillary involvement as demonstrated by the multiple linear
regression analysis.Fig. 3.Relationship between exercise systolic pulmonary arterial pressure and exercise left
atrial pressure. sPAP indicates systolic pulmonary arterial pressure; LAP indicates left atrial
pressure.Although populations, deﬁnition of exercise-induced pulmonary
hypertension and methods of investigations were not similar, the co-
existence of both mechanisms has already been demonstrated in
several studies. Hager et al. [13] performed exercise right heart cathe-
terization in 173 patients with resting sPAP b40 mm Hg, exercise sPAP
N40 mm Hg and shortness of breath. EIPH was deﬁned as the ratio be-
tween changes in mPAP and changes in CO N2 in patients b50 year
old and N3 in older ones. Pre- or post-capillary involvements were
deﬁned depending on exercise trans-pulmonary gradient, pulmonary
capillary wedge pressure values and changes in PVR. Of 53 patients
with EIPH, 6 had a pre-capillary involvement (11%) and 47 had exercise
diastolic dysfunction (89%), suggesting a complex pathophysiology.
In another study, Ciurzyński et al. [14] performed resting and post-
exercise assessment of sPAP in 85 patients with SSc. Twenty patientsTable 4
Signiﬁcant relationship between clinical and echocardiographic data and exercise sPAP.
Variables r2 p
Age 0.20 0.002
Resting PVR 0.39 b0.0001
Exercise RV end-diastolic diameter 0.10 0.06
Exercise LV end-systolic diameter 0.26 0.001
Exercise RV/LV diameter 0.17 0.02
Exercise LV e′, m/s 0.37 0.001
Exercise LAP 0.61 b0.0001
Exercise PVR 0.57 0.0004
Exercise-induced change in RV end-diastolic area 0.17 0.03
Exercise-induced change in LV end-diastolic diameter 0.20 0.006
Exercise-induced change in RV/LV ratio 0.17 0.02
PVR indicates pulmonary vascular resistance; RV, right ventricular; LV, left ventricular;
and LAP, left atrial pressure.
Fig. 4. Relationship between exercise left atrial pressure and exercise left atrial area. LAP
indicates left atrial pressure; LA indicates left atrial.
378 D. Voilliot et al. / International Journal of Cardiology 173 (2014) 373–379with an abnormal increase in sPAP (N20 mmHg) were referred to right
heart catheterization. Twelve patients had EIPH (mPAP N 30 mm Hg)
with elevated exercise pulmonary capillary wedge pressure
(N20 mm Hg) and 5 with pre-capillary participation. The authors
concluded that abnormal increase of PAP in SSc patients was more
commonly caused by LV diastolic dysfunction than pulmonary arterial
vasculopathy.
Our results are consistent with these previous studies and sug-
gest that EIPH in SSc may result from both pre- and post-capillary
mechanisms due to global myocardial and pulmonary micro-
vascular impairment.4.3. Factors inﬂuencing sPAP
The sPAP is strongly inﬂuenced by several factors such as age, pul-
monary disease and CO. Inﬂuence of age on sPAP is demonstrated in
several right heart catheterization studies in healthy subjects [39].
More recently, this relationship has been conﬁrmed in non-invasive
studies. Argiento et al. [20] have shown signiﬁcantly higher mPAP
both at rest and at peak exercise in subjects older than 50 year old
(respectively: 17, 3 vs. 14.9, 2.5; p b 0.05 and 35.9, 5.3 vs. 32.4,
7.4 mm Hg; p b 0.05). Similar results were found by Mahjoub et al.
[40] in an exercise echocardiography study with sPAP at peak exerciseFig. 5. Relationship between exercise systolic pulmonary arterial pressure and exercise
pulmonary vascular resistance. sPAP indicates systolic pulmonary arterial pressure;
PVR indicates pulmonary vascular resistance, WU, indicates Woods unit.of 45 ± 7 mm Hg for b30-year old subjects to 58 ± 7 mm Hg for
N70-year old subjects. In our study, the EIPH group was signiﬁcantly
older but after adjustment for age, exercise E/e′ ratio remained
associated with sPAP.
The sPAP is also related to the CO. In healthy subjects, there is a linear
relationship between CO, age and sPAP [4]. We did not ﬁnd signiﬁcant
difference in LVCO between the 2 groups, with even a trend toward
lower exercise LVCO in the EIPH group and a lower exercise-induced
change in LVCO. Furthermore, the slope of mPAP–LVCO relationship
remained signiﬁcantly higher in this group.
Finally, pulmonary diseases may inﬂuence sPAP. There is a close re-
lationship between pulmonary function and pulmonary circulation and
especially in SScwith interstitial lung diseases [41]. No signiﬁcant differ-
ences between the 2 groups regarding variables of lung function tests
were found in the present study.
4.4. Limitations of the study
Themain limitation of our study is the relative small size of the pop-
ulation. However, it reﬂects the low incidence of SSc. For instance, the
absence of relationship between workload or pulmonary acceleration
time (Tables 1 and 2) and EIPH could mainly be due to a type II error.
Small LV volumes reported could be related to foreshortening views
and may also explain the low LVCO reported. However this underesti-
mation affects the whole population. Consequently, this limitation
does not inﬂuence the reliability of the main results of this study,
which is the demonstration that estimated LV ﬁlling pressure during
exercise is an independent determinant of EIPH.
As previously described [20,21] and underlined by several recent re-
views [4–6], the slope of the mPAP–LVCO relationship is probably the
best way to demonstrate an abnormal increase in PAP during exercise
and therefore for the diagnosis EIPH. However, duration of exercise in
our population was really short and we rather focused on LV systolic
and diastolic function. In addition, it has been demonstrated that for a
LVCO less than 10 L/min, the upper limit of normal value of mPAP is
34 mm Hg [4], corresponding to a sPAP of 55 mm Hg. In our cohort, all
but 4 patients in the no EIPH group exhibited a peak exercise LVCO
N10 L/min. As echocardiography assessment of sPAP most of the time
underestimates this value, a cut-off value of 50mmHg (securitymargin
of 5mmHg) is acceptable in this kind of population. However, wemade
an estimation of the slope of mPAP–LVCO relationship, using the ratio
between changes in mPAP and changes in LVCO (peak–rest value). In-
terestingly, even in the no EIPH group some patients had a slope of
mPAP–LVCO relationship N3mm Hg/L/min (n= 5, 21%). Asmentioned
in the Limitations of the study section, this could be related to themeth-
od of assessment of LVCO that can lead to an underestimation of LVC
and thus an overestimation of the slope of mPAP–LVCO relationship.
However, our results are in line with recent paper from Gargani et al.
[19] reporting a change of 3.1 ± 2.7 mm Hg/L/min in the subset of
patients with exercise sPAP b 50 mm Hg.
Regarding the exercise protocol, an increment of 25Wmay seem to
be excessive for chronic ill patients. However, this protocol is in line
with other studies on SSc [19,42] and also on other ﬁelds of research
such as valvular heart diseases [17,18], congenital heart disease [43] or
pulmonary arterial hypertension [44]. In addition, a dynamic protocol
is necessary to avoid the increase in systemic vascular resistance and
abrupt change in intra-thoracic pressure occurring during resistive
exercise and that can lead to unpredictable effects on the pulmonary
circulation [4].
5. Conclusion
EIPH is frequent in patients with SSc (47%) and may be detected
using exercise echocardiography. In patients with EIPH, our results
suggest the potential role of increased exercise LV ﬁlling pressure and
increased PVR. Exercise echocardiography could be useful for the
379D. Voilliot et al. / International Journal of Cardiology 173 (2014) 373–379screening and the understanding of the pathophysiologicalmechanisms
leading to PH in patientswith SSc. Further studies are needed to conﬁrm
these results and their impact on the outcome.
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